PE20231379A1 - Agonista de receptor de melanocortina-4 amorfo - Google Patents

Agonista de receptor de melanocortina-4 amorfo

Info

Publication number
PE20231379A1
PE20231379A1 PE2023001493A PE2023001493A PE20231379A1 PE 20231379 A1 PE20231379 A1 PE 20231379A1 PE 2023001493 A PE2023001493 A PE 2023001493A PE 2023001493 A PE2023001493 A PE 2023001493A PE 20231379 A1 PE20231379 A1 PE 20231379A1
Authority
PE
Peru
Prior art keywords
compound
amorphous
melanocortin
receptor agonist
pyrrolidin
Prior art date
Application number
PE2023001493A
Other languages
English (en)
Inventor
Jin Ok Ham
Ho Yeon Lee
Ji Yoon Kim
Sung Won Kim
Seul Ah Chun
Sang Dae Lee
Jong Won Park
Original Assignee
Lg Chemical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lg Chemical Ltd filed Critical Lg Chemical Ltd
Publication of PE20231379A1 publication Critical patent/PE20231379A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Referido a un compuesto amorfo de formula 1, o una sal farmaceuticamente aceptable del mismo, caracterizado porque R1 es alquilo de C2-C5. Este compuesto derivado de carboxamida heteroaromatica es inhibidor de la calicreina plasmatica. En donde dicho compuesto es clorhidrato de N-((3S,5S)-1-((3S,4R)-1-(ter-butil)-4-5 (4-cloro-fenil)pirrolidin-3-carbonil)-5-(morfolin-4-carbonil)-pirrolidin-3-il)-N-((1s,4R)-4-metilciclohexil)isobutiramida. Tambien se refiere a un metodo para preparar dicho compuesto amorfo o la sal farmaceuticamente aceptable del mismo, una composicion farmaceutica que comprende dicho compuesto, y su uso para prevenir o tratar obesidad, diabetes, inflamacion o disfuncion erectil.
PE2023001493A 2020-10-29 2021-10-29 Agonista de receptor de melanocortina-4 amorfo PE20231379A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20200142399 2020-10-29
PCT/KR2021/015467 WO2022092908A1 (ko) 2020-10-29 2021-10-29 무정형의 멜라노코르틴-4 수용체 작용제

Publications (1)

Publication Number Publication Date
PE20231379A1 true PE20231379A1 (es) 2023-09-07

Family

ID=81384115

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2023001493A PE20231379A1 (es) 2020-10-29 2021-10-29 Agonista de receptor de melanocortina-4 amorfo

Country Status (13)

Country Link
EP (1) EP4219471A4 (es)
JP (1) JP2023548162A (es)
KR (1) KR20220057469A (es)
CN (1) CN116419757A (es)
AU (1) AU2021370071B2 (es)
CA (1) CA3195214A1 (es)
CL (1) CL2023001221A1 (es)
CO (1) CO2023006514A2 (es)
IL (1) IL302425A (es)
MX (1) MX2023004654A (es)
PE (1) PE20231379A1 (es)
WO (1) WO2022092908A1 (es)
ZA (1) ZA202305591B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022139441A1 (ko) * 2020-12-22 2022-06-30 주식회사 엘지화학 무정형의 멜라노코르틴 수용체 작용제 및 이의 제조방법

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU766191B2 (en) * 1999-06-04 2003-10-09 Merck & Co., Inc. Substituted piperidines as melanocortin-4 receptor agonists
CA2433025A1 (en) * 2001-01-23 2002-08-01 Chaoyu Xie Substituted piperidines/piperazines as melanocortin receptor agonists
AR044510A1 (es) 2003-04-14 2005-09-14 Merck & Co Inc Procedimiento e intermedios para preparar acidos carboxilicos de pirrolidina
KR100661118B1 (ko) * 2003-11-12 2006-12-26 주식회사 엘지생명과학 멜라노코틴 수용체의 항진제
TWI332501B (en) * 2006-07-14 2010-11-01 Lg Life Sciences Ltd Melanocortin receptor agonists
UA99555C2 (en) * 2008-11-12 2012-08-27 Элджи Лайф Саенсез Лтд. Melanocortin receptor agonists
MX2019009463A (es) 2017-02-08 2019-12-16 Tilray Inc Metodo y aparatos para procesamiento de canabis a traves de energia radiante de baja presion.
MX2021014074A (es) * 2019-11-07 2021-12-10 Lg Chemical Ltd Agonistas de receptor de melanocortina-4.

Also Published As

Publication number Publication date
AU2021370071B2 (en) 2024-01-11
JP2023548162A (ja) 2023-11-15
EP4219471A1 (en) 2023-08-02
EP4219471A4 (en) 2024-03-13
CN116419757A (zh) 2023-07-11
AU2021370071A1 (en) 2023-06-01
IL302425A (en) 2023-06-01
CL2023001221A1 (es) 2023-11-03
CA3195214A1 (en) 2022-05-05
KR20220057469A (ko) 2022-05-09
ZA202305591B (en) 2024-09-25
WO2022092908A1 (ko) 2022-05-05
CO2023006514A2 (es) 2023-07-31
MX2023004654A (es) 2023-05-18

Similar Documents

Publication Publication Date Title
PE20220766A1 (es) Agonistas de receptor de melanocortina-4
RU2424240C2 (ru) Антибактериальные производные пиперидина
PE20161342A1 (es) Combinaciones de inhibidores de histona desacetilasa y farmacos inmunomoduladores
PH12019501707A1 (en) N-[4-fluoro-5-[[(2s,4s)-2-methyl-4-[(5-methyl-1,2,4-oxadiazol-3-yl)methoxy]-1-piperidyl]methyl]thiazol-2-yl]acetamide as oga inhibitor
MX2022011365A (es) Derivados de biarilo como inhibidores de la interaccion proteina-proteina de yap/taz-tead.
PE20110367A1 (es) DERIVADOS DE 4-CIANO-4-FENIL-PIRROLIDIN-2-CARBOXAMIDAS SUSTITUIDAS COMO INHIBIDORES DE LA INTERACCION p53-MDM2
PE20061373A1 (es) Composicion farmaceutica que contiene 'n-(2-cloro-6-metilfenil)-2-[[6-[4-(2-hidroxietil)-1-piperazinil]-2-metil-4-pirimidinil]amino]-5-tiazolcarboxamida
PE20231379A1 (es) Agonista de receptor de melanocortina-4 amorfo
TW200716644A (en) Aspartyl protease inhibitors
MX2009006493A (es) Compuestos inhibidores activos, citoesqueleticos, de la quinasa de rho, composiciones y usos.
AR061873A1 (es) Derivados de pirrolotriazina inhibidores de tirosinquinasas, composiciones farmaceuticas que los contienen utiles para el tratamiento de enfermedades proliferativas.
ECSP078003A (es) Inhibidores de aspartil proteasas
PE20050772A1 (es) Piperidinilcarbonil-pirrolidinas como agonistas de melanocortina
CO6140054A2 (es) Compuestos de dialquilfenilo con actividad agonista del receptor beta2 adrenergico y antagonista del receptor muscarinico
CO6270285A2 (es) Derivados de 4-[(4-amino-1, 3, 5-triazin-2-il)amino]-n-arilmetilcicloalquilcarboxamida
CA2409741A1 (en) Tnf-.alpha. production inhibitors
PH12020552244A1 (en) Heterocyclic compounds as trk inhibitors
MX2024009925A (es) Composiciones y metodos para tratar trastornos del snc.
PE20190106A1 (es) Inhibidores del potenciador del homologo zeste 2
PE20212067A1 (es) Forma cristalina de 1-(1-oxo-1,2-dihidroisoquinolin-5-il)-5-(trifluorometil)-n-(2- (trifluorometil)piridin-4-il)-1h-pirazol-4-carboxamida monohidratada
PH12021550687A1 (en) Pharmaceutical composition for oral administration comprising aminopyrimidine derivative or its salt
PE20061418A1 (es) Composiciones farmaceuticas de 4-[(ciclopropanocarbonilamino)metil]-2-(2,6-dioxopiperidin-3-il)isoindol-1,3-diona para el tratamiento o prevencion de lupus cutaneo
BR112013031121A2 (pt) composto de acordo com a fórmula i a v, ou um sal farmaceuticamente aceitável, solvato, polimorfo, ou pró-droga do mesmo; composto; polimorfo de sal cloridrato de 2-morfolino-n-(3-(4-(5-(pirrolidina-1-carbonil)-1h-pirrol-3-il)tiazol-2-il)acetamida (fórmula i); ingrediente ativo constituído do mesmo; composição farmacêutica; polimorfo de 2-morfolino-n-(3-(4-(5-(pirrolidina-1-carbonil)1h-pirrol-3-il)tiazol-2-il)fenil)acetamida (fórmula i); ingrediente ativo constituído do mesmo; uso de um composto ou sal farmaceuticamente aceitável, solvato, polimorfo ou pró-droga do mesmo e uso de um polimorfo ou ingrediente ativo de sal cloridrato de 2-morfolino-n-(3-(4-(5-(pirrolidina-1-carbonil)-1h-pirrol-3-il)tiazol-2il)tiazol-2-il)fenil)acetamida (fórmula i) e uso de um polimorfo ou ingrediente ativo de 2-morfolino-n-(3-(4-(5-(pirrolidina-1-carbonil)-1h1pirrol-3-il)tiazol-2-il)fenil)acetamida(fórmula i) na fabricação de um medicamento
PE20221630A1 (es) Derivado de amino arilo novedoso util como inhibidor de diacilglicerol aciltransferasa 2 y uso del mismo
CA3156340A1 (en) N-(1H-IMIDAZOL-2-YL)BENZAMIDE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING IT AS ACTIVE SUBSTANCE